The present invention provides a solid composition containing an amorphous poorly water-soluble material, and a method for producing the same. The solid composition of the present invention is a solid composition containing an amorphous poorly water-soluble material (1a), hydroxypropylmethyl cellulose (2), and one or more types of water-soluble polysaccharides (3) other than hydroxypropylmethyl cellulose, and is characterized in that an XRD analysis value of the solid composition is 4.0% or less.

The present invention provides a solid composition containing an amorphous poorly water-soluble material, and a method for producing the same. The solid composition of the present invention is a solid composition containing an amorphous poorly water-soluble material (1a), hydroxypropylmethyl cellulose (2), and one or more types of water-soluble polysaccharides (3) other than hydroxypropylmethyl cellulose, and is characterized in that an XRD analysis value of the solid composition is 4.0% or less.

The present invention provides a novel compound having an excellent β-lactamase inhibitory effect. The present invention provides: a compound which has an excellent β-lactamase inhibitory effect, and is represented by formula (1a), (1b) or (11); or a pharmaceutically acceptable salt thereof. This compound provides a prophylactic or therapeutic agent effective for bacterial infections when used in combination with β-lactam-based drugs or used as a single agent. The present invention also provides a prophylactic or therapeutic agent effective for treating various diseases, by being used in combination with β-lactam-based drugs.

The present invention provides a novel compound having an excellent β-lactamase inhibitory effect. The present invention provides: a compound which has an excellent β-lactamase inhibitory effect, and is represented by formula (1a), (1b) or (11); or a pharmaceutically acceptable salt thereof. This compound provides a prophylactic or therapeutic agent effective for bacterial infections when used in combination with β-lactam-based drugs or used as a single agent. The present invention also provides a prophylactic or therapeutic agent effective for treating various diseases, by being used in combination with β-lactam-based drugs.

This invention is directed to compositions and methods for modulating glucose homeostasis.

This invention is directed to compositions and methods for modulating glucose homeostasis.

The present disclosure generally relates to compositions and methods for modulating mitochondrial dynamic and function in skin conditions.

The present disclosure generally relates to compositions and methods for modulating mitochondrial dynamic and function in skin conditions.

This disclosure describes the use of a phosphodiesterase-5 (PDE5) inhibitor to reduce an individual's desire to smoke and/or frequency of smoking. In some embodiments, the PDE5 inhibitor is sildenafil (e.g., Viagra).

This disclosure describes the use of a phosphodiesterase-5 (PDE5) inhibitor to reduce an individual's desire to smoke and/or frequency of smoking. In some embodiments, the PDE5 inhibitor is sildenafil (e.g., Viagra).